Aggressive juvenile fi bromatosis of the jawbones is a rare tumor presenting as infi ltrative mass with unpredictable evolution. We report herein a 17-year-old student with a 6-month history of radiologically proven resorption of a part of the mandible, lingual displacement of tooth 34 and malocclusion. Alveolar ridge resorption and three dark-brown foci in the bone were seen after the tooth was extracted. Histological study showed the tumor tissue to have a bundle-like structure; immunohistochemically it was positive for vimentin, smooth muscle actin, β-catenin, Ki-67 (5%), and negative for desmin and cytokeratin 34bE12. The golden standard in the diagnostics of desmoid fi bromatoses is the nuclear or membrane expression of β-catenin, which is found in 90% of the cases. Differential diagnosis include mandibular fi broma, well-differentiated fi brosarcoma, fi brosing histiocytoma, and infi ltration from adjacent soft-tissue tumor. Aggressive juvenile fi bromatosis should be managed by radical excision. Local recurrences are not rare, but metastases do not develop. In rare cases this type of fi bromatosis has been known to regress spontaneously. Aggressive fi bromatosis is a diagnostic challenge, since it remains in the grey zone between benign and malignant lesions of the oral cavity.
INTRODUCTION
Fibromatoses represent a group of non-metastasizing locally aggressive tumors with borderline malignancy. Being categorised as the "grey zone" between benign and malignant tumors they present a challenge for clinicians and pathologists. Fibromatoses develop before 40 years of age (childhood and juvenile age prevail) in any part of the body. Their prevalence in the total population is extremely low -0.2-0.5 per 100000 newly found cases per year 1 , and the oral cavity is the place of origin of only 3-10%. 2 Aggressive juvenile fi bromatosis of the mandible is not reported widely in the literature.
Fibromatoses are divided into two broad categories: superfi cial and deep. 3, 4 The superfi cial fi bromatoses (palmar and plantar) are usually small (< 5 cm) slow-growing lesions. Surrounding tissues are rarely involved in their development. Deep fi bromatoses (desmoids) are fast growing lesions, which frequently reach signifi cant size, if their localization allows so, e.g. in the intra-abdominal type of desmoid. They are referred to as aggressive fi bromatoses for their infi ltrative pattern of
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growth, but also because of their high recurrence rate (as frequently as 70%).
The fi bromatoses of the head and neck belong to the group of extra-abdominal fi bromatoses (60% of the cases). Only deep fi brotic proliferations occur in the oral cavity: they are sporadic, familial adenomatous polyposis associated and multicentric. They present as variously sized masses, localized centrally in the jawbones or the soft tissues. Because soft tissue and intraosseous aggressive fi bromatoses of the head and neck are histologically indistinguishable and because of their mutual infi ltration, they are usually termed desmoid fi bromatosis. 4, 5 We present herein a case of rare aggressive mandibular fi bromatosis. (Fig. 3) . Their nuclei were ovoid, (Fig. 4) 
; desmin (-); cytokeratin 34bE12 (-); estrogen receptor (+); Ki-67 (MIB -1) (+) in approximately 5% of the nuclei. Pathomorphological diagnosis: Aggressive juvenile mandibular fi bromatosis. The patient's condition is followed up by an oral
cluded in the treatment of surgically unresectable fi bromatoses, even though they might be benign. 7 Radiotherapy is given in high doses (> 50 Gy) 6 , and yet 20-36% of the patients have recurrences. 2 Anti-estrogen hormonal therapy for aggressive fi bromatosis is based on its prevalence in women in fertile age (up to 80%) and its faster growth during pregnancy. Immunohistochemically, as has been shown by our study, the tumor cells are positive for estrogen receptors (especially in Gardner syndrome). This fi nding may be related to the report of stabilization and even regression of the process by tamoxifen therapy. 8 Benefi cial effect has been reported in using NSAIDs as well. 3, 8 Chemotherapy is used in cases of impossible or unsuccessful surgical and radiological approaches.
Myofi broblastic immunophenotype is supposed in fi bromatosis: vimentin (+), actin (+), variable desmine. The golden standard in the diagnosis surgeon. After 1 year of follow-up no recurrence occurred and the bone alterations in the jaw were stabilized (Fig. 5) .
DISCUSSION
The etiology of fi bromatoses is not completely elucidated and is probably quite diverse: mutations in the adenomatous polyposis coli-gene in chromosome 5q22 6 , sporadic cases with mutation in the β-catenin-gene or the occurrence of scar on the spot, have been described.
The fi bromatosis is an infi ltrative tumor that is diffi cult to excise, possessing high recurrence potential. It is recommended that it is excised at least 2-3 cm within normal tissue. 1,2 Radiotherapy, chemotherapy or endocrine therapy should be inof desmoid fi bromatoses is β-catenin -a genetic immunohistochemical marker. Its nuclear and membrane expression are observed in more than 90% of the cases of fi bromatosis, associated with Gardner syndrome and in sporadic fi bromatoses. The proliferative nuclear index is usually lower than the one presented in this case (5% -a predictor of recurrence).
The differential diagnosis clinically includes eosinophilic granuloma (but without fever), osteoblastoclastoma and well differentiated fi brosarcoma. 1, 3, 4, 7 Clinically it is quite similar to fi bromatosis in location, age range 5, 9 and infi ltrative presentations. The morphological study has to eliminate the fi rst two options. The fibrosarcoma presents with a higher mitotic index and signs of cellular atypism Fibromatoses recur in the fi rst few years. Ogunsalu and Barclay 10 propose staging of histologically verifi ed clinically aggressive fi bromatoses on 4 levels: A -recurrence after aggressive surgical treatment; B -no recurrence after aggressive surgical treatment; C -no recurrence after non-aggressive surgical treatment; D -tumor regression without defi nitive surgical treatment.
CONCLUSION
Aggressive fi bromatosis of the jawbones is extremely rare. Clinically, the tumor tends to present as malignant -it erodes the bone, infi ltrates the surrounding tissues, and recurs. The microscope fi nding is also not always conclusive. Crucial for the diagnosis is the immunohistochemical expression of β-Catenin. The good collaboration between the clinician and the pathologist helps in differentiating this lesion with borderline malignancy from the many other types of fi broblastic processes -reactive and neoplastic, and specifi cally from the well-differentiated fi brosarcoma.
